Passive Real Estate Investments β’ Cash Flow Investing β’ Real Estate Syndication β’ Real Estate Investing β’ Passive Income
August 7
Passive Real Estate Investments β’ Cash Flow Investing β’ Real Estate Syndication β’ Real Estate Investing β’ Passive Income
β’ Serve as Chief Compliance officer for RM Securities, a registered broker-dealer (BD). β’ Serve as Chief Compliance officer for RM Adviser, a registered investment advisor (RIA). β’ Partner with senior management to ensure that FINRA, SEC and other regulatory requirements are properly addressed and that required BD or RIA processes are successfully implemented, documented, and tested. β’ Work with technology and product teams to spec out compliant technology to automate compliance functions and support new initiatives. β’ Serve as regulatory compliance subject matter expert for the company, working with outside counsel as needed. β’ Review marketing materials, draft disclosures, and edit copy for compliance with BD and RIA requirements. β’ Manage compliance-related forms and filings. β’ Work with outside counsel to manage legal needs for two public, non-traded REITs managed by the RIA including 1-A/As, 253G2s, 1-Us and 1-SAs. β’ Advise on legal aspects of the company, including assessing and advising on current and future business structures and legal entities. β’ Manage all annual exams / communication and coordination with FINRA and the SEC.
β’ 8+ years of compliance experience; proficient with BD and RIA securities laws and regulations. β’ Licensed attorney. β’ Highly ethical and value compliance and confidentiality. β’ Pro-active, positive and driven. You like to take ownership. β’ Willing to do what it takes to get the job done. β’ Detail-oriented and organized. β’ Enjoy fast-paced environments. β’ Excellent communication skills - both oral and written. β’ You want to make a real impact on a business as an executive. β’ Active Series 24 preferred. β’ Real estate and fund management experience a plus.
Apply NowJuly 19
11 - 50
Lead global regulatory strategy for innovative therapeutics degrading extracellular and membrane-bound proteins.
May 3
51 - 200